What is Wegovy worth to your employer? Companies wrestle with obesity drugs’ costs, long-term value.

Amid mounting evidence of obesity drugs’ long-term health benefits, thorny questions persist about their value to employers

Previous post Blood-plasma group’s shares rally after short seller slashes negative bet
Next post Choice Hotels slams Wyndham’s claims of antitrust risk in its $85-a-share bid for its smaller rival